The marketer teaching Pfizer to talk like a human

Most people who join a company in their twenties are gone within a few years. Susan Rienow joined Pfizer in 2001 and stayed. Not for two years, not for five - for twenty-three, and counting. In that time she moved her life through Belgium, Japan, Australia, South Korea and the United Kingdom, learned each new market like a language, and quietly built the kind of resume that is impossible to fake because you cannot rush it. In July 2024 all of it added up to one title: Global Chief Marketing Officer of Pfizer.

It is a strange job to hand to a company that, for most of its 175 years, preferred to talk like a laboratory. Pfizer's default voice was clinical - trial data, mechanisms of action, the careful hedging of regulatory language. Rienow's project, stated plainly, is to change that. Not to abandon the science, but to make it legible. To get a drug company to sound like something a person might actually want to listen to.

A history major who fell into pharma

Rienow did not set out to sell medicine. She grew up in North Carolina, one of seven children, the daughter of a heart surgeon - a household where the stakes of medicine were the family business but the vocabulary of marketing was not. She studied history at Boston University, then took an MBA at NYU's Stern School of Business. Her first working years were spent consulting in Boston, advising a rotating cast of companies. One of those clients was Pfizer. In 2001 the client became the employer, and she joined as a senior market research manager - the person whose job is to figure out what patients and doctors actually want, then translate it into something the business can act on.

That starting point matters. Rienow did not arrive as a brand visionary handed a megaphone. She arrived as someone paid to listen. Two decades later, running global marketing, she still frames the work the same way - as a question of relevance before reach.

The passport as a career strategy

The conventional advice for climbing a large company is to plant a flag and defend it - own one market, one brand, one region, and make yourself indispensable there. Rienow did close to the opposite. She kept moving. Senior manager of US marketing. Senior brand manager for central nervous system and pain treatments across emerging markets and Europe. Acting regional marketing director for the same category across several markets. Regional brand director on a European specialty team working in hemophilia. Each move meant being the newcomer again, learning a market from scratch, rebuilding credibility with a fresh set of colleagues.

She landed in the UK in 2015 to lead the critical care division, then took on the Hospital business unit and Essential Health. When the vaccines business became, for a stretch, the most scrutinized corner of the entire company, she was running it in Britain. In early 2023 she became Pfizer UK's Managing Director and Country President, and went on to serve as President of the ABPI, the trade body for the British pharmaceutical industry. Running a whole country's business is where a lot of executives stop. For Rienow it turned out to be the on-ramp.

A drug company at the Super Bowl

The clearest evidence of what Rienow wants Pfizer's marketing to become arrived in the most expensive real estate in advertising. Pfizer ran a cancer-themed Super Bowl spot called "Knock Out." Instead of the usual category conventions - the soft focus, the fine print, the careful distance - it went for something direct and human. When the ad-testing firm System1 ran the numbers, it scored as the strongest pharmaceutical ad it had ever measured. The follow-up campaign, "One More," debuted around ASCO, the big annual cancer research meeting.

What Rienow keeps pointing at is not the trophy. It is the behavior. Her stated test for a campaign is whether it moved someone to do something - in this case, a screening message that reached a mass audience. Awards measure taste. Action, in her telling, measures truth.

Figures cited by Rienow and Pfizer in 2025 marketing talks. Bars indexed for scale, not a shared axis.

Betting the brand on one word

Behind the advertising sits a strategic wager. Roughly 40% of Pfizer's research pipeline is now pointed at oncology, with a public ambition to deliver eight breakthroughs in cancer treatment by 2030. A marketing chief's job, in that context, is to make the brand story match the science story - to give a sprawling, complicated company a spine people can grasp. Rienow's answer has been to lead with human impact and let the science be the reason it is credible, rather than the other way around.

The AI question, answered by someone who ships

Ask most executives about artificial intelligence and you get a fog of buzzwords. Rienow, who has to actually deploy it across a global marketing operation, is more specific. At Pfizer, generative AI now drafts and adapts creative, speeds the legal and medical review that has always been pharma marketing's slowest gear, and personalizes messages at a scale no human team could reach by hand. But she draws a clean line at what the machine does not do: it does not decide what to say.

That distinction - speed from the machine, meaning from the human - is the tidy version of her whole philosophy. She has said that cancer touches 40% of Americans, that it has touched her own family, and that this is exactly the sort of thing an algorithm can locate but only a person can understand. Use the tool for the reach. Keep the reason for yourself.

What she does when she is not marketing

For all the scale of the job, the picture Rienow paints of herself outside it is small and ordinary in a good way. She is married with a teenage son. She unwinds by gardening and walking her dog. After a life of time zones - a childhood in North Carolina among six siblings, a career that ran through four continents - the counterweight to running global marketing turns out to be a patch of garden and a dog that needs its walk.

There is a lesson buried in the arc, and it is not the usual one about ambition. Rienow did not leap. She accumulated. Twenty-three years of understanding one industry from the inside is a kind of moat no competitor can copy and no shortcut can build. Breadth looked like distraction for a long time - all those postings, all that starting over - right up until the day it looked like the only person qualified to run the whole board. Now she has the board. The question she is really answering is whether a company built on the language of science can learn to speak, convincingly, in the language of people. So far, the numbers are on her side.